International, commercial stage pharmaceutical company focused on anaesthesia and perioperative therapy
Primex offers a range of anaesthesia products for various medical procedures, including a new oral solution for paediatric sedation
We keep bringing new medications for anaesthesia
Established in 2010, Primex owns, markets and sells high-quality anaesthetic pharmaceuticals worldwide Primex Pharmaceuticals will continue to identify and bring to the market new medications that complete the Triad of Anaesthesia.
Fast-growing global speciality company
Established in 2010, Primex owns, markets and sells high-quality anaesthetic pharmaceuticals worldwide.
Primex’s activities consist of managing two core functions:
global regulatory affairs and global distribution and marketing.
Manufacturing is outsourced
to partners under the strictest quality controls, ensuring full financial flexibility, as a result, the company does not support R&D risk.
Niche anaesthetics offering
The company has recently acquired global rights to OZALIN, a drug addressing unmet needs in paediatric sedation.
Lean, de-risked, efficient and scalable business model
Significant management expertise in development, external manufacturing and commercialisation
International
- Local marketing and distribution knowledge
- Knowledge to screen, locate and potentially acquire attractive new drug candidates
- Demonstrated track record of M&A transactions
In-depth knowledge
- Presence in several continents offering geographical diversification
- Demonstrated track record of commercialisation and market ecpansion
- Broad and extensive knowledge of international pharmaceutical regulation and dynamics
Efficient and fast
- Knowledgeable and lean organisation enables to efficiently identify and transact on new opportunities
- Demonstrated track record in EXECUTION
- Hightly focused on cost management
Organization & Capabilities
- Finance
- Legal
- Mergers & acquisitions
- Licensing
- External manufacturing
- Supply chain
- Partnership management
- MKT & commercial
- Medical affairs
- Quality
- Regulatory affairs
- Pharmacovigilance
Strong growth achieved since inception in 2010
Fast-growing global specialist company
Senior Leadership Team
Tomaso Dameno
CEO
Group CEO since 2024
Previously Head of Operations since 2018
Michael Augsberger
CFO
Since 2024
Bareket Gelbhart
Head of Business Development
Since 2025
Board Members
Panu Paappanen
Chairman
Joonas Vaahtera
Board Member
Petri Laine
Board Member
Jany Mengelkamp
Board Member & Co-Founder
Jostein Davidsen
Board Member
Pier Vincenzo Colli
Board Member
Join our team!
Send your application
Developing a lean business model enabling quick scalability through acquisitions of new drugs
• Broad portfolio of specialty products
• Experienced senior management and regulatory teams
• Lean commercially focused organisation
• Global distribution network
• Scalable business model
• Unique global niche strategy
• Multiple avenues for growth and value creation
